News

The trials, which will begin during the second half of 2008, will test AZD6244 (ARRY-886) in combination with a cytotoxic chemotherapeutic agent; one trial will be in melanoma

This relationship will provide Duke investigators access to the company’s core technologies, Laser Capture Microdissection and Reverse phase Protein Microarray. The proprietary combination of these technologies provides a

The study was a randomized, double-blind, placebo-controlled, cross-over, single-rising dose study conducted with healthy male volunteers. Objectives of the study included assessments of the safety, tolerability, and pharmacokinetics

In the private placement, Sonomax intends to issue a maximum of 13,333,333 units at a price of $0.15 per unit, for maximum proceeds to Sonomax of $2 million.

These devices facilitate manual x-ray contrast media injections during angiography procedures performed in the cardiac catheterization laboratory and interventional radiology suite. Under the terms of the agreement, Covidien

In view of the current market conditions, the difficulty in raising finance at the current low share price, and the problems associated with the AD923 device which has

The $35 million investment represents the second major investment in ProCure by McClendon Venture Company (MVC) and pushes the firm’s total investment in the growing proton therapy treatment

As part of the R&D funding for Kevetrin, the company has completed a $400,000 9% secured convertible debenture financing. The debentures and concomitant interest come due December 1,

Sirtex received an investigational device exemption from the FDA to conduct the trial. The trial is actively recruiting patients at Thomas Jefferson University’s Kimmel Cancer Center in Philadelphia,